Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11804557 | 1.00 | AKR1C4 (0.38) | AKR1C4AKR1C3AKR1C2METAP2ALOX15 | |
| SCHEMBL10385820 | 0.76 | AKR1C4 (0.40) | AKR1C4AKR1C3AKR1C2METAP2 | |
| SCHEMBL7604302 | 0.76 | PRKCA (0.36) | — | |
| SCHEMBL27922826 | 0.75 | ALOX15 (0.30) | ALOX15 | |
| SCHEMBL896555 | 0.73 | AKR1C4 (0.45) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL1931831 | 0.73 | AKR1C4 (0.45) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL2477329 | 0.73 | ALOX15 (0.31) | ALOX15 | |
| SCHEMBL10712782 | 0.69 | AKR1C4 (0.30) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL10713706 | 0.69 | AKR1C4 (0.30) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL10919799 | 0.69 | ALOX15 (0.31) | AKR1C4AKR1C3AKR1C2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020102280-A1 | Solvent systems for pharmaceutical agents | LYOTROPIC THERAPEUTICS, INC. | 2002-08-01 | — | — | US | claimed |
| US-6121234-A | ORALLY COADMINISTERING TO MAMMAL PHARMACEUTICAL COMPOUND AND ESSENTIAL OIL | AVMAX, INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0831870-A4 | USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS | AVMAX INC (US) | 1998-09-16 | — | — | EP | claimed |
| EP-0831870-A1 | USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS | Avmax, Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5716928-A | ADMINISTERING DRUG CONCURRENTLY WITH ESSENTIAL OIL | AVMAX, INC. (US) | 1998-02-10 | — | — | US | claimed |
| US-5665386-A | Use of essential oils to increase bioavailability of oral pharmaceutical compounds | AVMAX, INC. (US) | 1997-09-09 | — | — | US | claimed |
| WO-1996040192-A1 | USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS | AVMAX, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20140271863-A1 | HOT WASHABLE POLY-N-ISOPROPYLACRYLAMIDE HYDROGEL DELIVERY SYSTEMS | Textile-Based Delivery, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8449863-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8128906-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8128905-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110253584-A1 | WATER- AND HEAT-RESISTANT SCRATCH-AND-SNIFF COATING | ENCAPSYS, LLC | 2011-10-20 | — | — | US | disclosed |
| EP-2364205-A2 | A FRAGRANCE-DELIVERY COMPOSITION COMPRISING BORON AND PERSULFATE ION-CROSSLINKED POLYVINYL ALCOHOL MICROCAPSULES AND METHOD OF USE THEREOF | APPLETON PAPERS INC. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2003106382-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1345589-A1 | SOLVENT SYSTEMS FOR PHARMACEUTICAL AGENTS | Lyotropic Therapeutics, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030022242-A1 | Particle for use in the absorption of one or more materials in preferential environments | LYOTROPIC THERAPEUTICS, INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000236-A1 | PARTICLES WITH IMPROVED SOLUBILIZATION CAPACITY | LYOTROPIC THERAPEUTICS, INC (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020102280-A1 | Solvent systems for pharmaceutical agents | LYOTROPIC THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002043696-A1 | SOLVENT SYSTEMS FOR PHARMACEUTICAL AGENTS | LYOTROPIC THERAPEUTICS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-3941828-A | Process for the preparation of cyclic ketones | FIRMENICH SA (CH) | 1976-03-02 | — | — | US | disclosed |